
Q32 Bio Inc. (NASDAQ:QTTB) stock is trading higher on Monday, with a session volume of 70.56 million compared to the average volume of 217.704 thousand as per data from Benzinga Pro.
Q32 Bio on Monday sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics Inc. (NASDAQ:AKBA).